Physician profile
Peter C Nishan
NPI 1407810435
$8,913.73
in general payments reported to CMS, 2019-2025
31 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,009 · 2020: $92.98 · 2021: $246 · 2022: $1,234 · 2023: $2,237 · 2024: $802 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443 · Travel and Lodging: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,442.60 |
| Travel and Lodging | $888.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,893.18 | 2019-2025 | Mitraclip, Triclip |
| Novartis Pharmaceuticals Corporation | $761.04 | 2019-2025 | |
| Boston Scientific Corporation | $639.63 | 2022-2023 | Watchman Access System |
| Amgen INC. | $567.24 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $309.90 | 2019-2024 | Xarelto |
| Medtronic, INC. | $194.55 | 2022-2025 | Corevalve Evolut R |
| Pfizer INC. | $182.25 | 2019-2025 | |
| Irhythm Technologies, INC. | $181.99 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.10 | 2019-2023 | Jardiance |
| Edwards Lifesciences Corporation | $137.77 | 2023-2024 | Pascal |
| Astrazeneca Pharmaceuticals LP | $98.00 | 2019-2024 | Farxiga, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $96.58 | 2022-2023 | |
| Cvrx, INC. | $79.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $75.85 | 2020-2023 | |
| Esperion Therapeutics, INC. | $74.95 | 2021-2024 | Nexletol |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $63.62 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $54.58 | 2022-2024 | Eliquis |
| Biosense Webster, INC. | $44.18 | 2023 | Nuvision Ice Catheter |
| Kiniksa Pharmaceuticals International, Plc | $36.00 | 2024 | Arcalyst |
| Heartflow, INC. | $30.65 | 2019-2024 | |
| Abiomed | $28.20 | 2024 | Impella |
| Novo Nordisk INC | $26.21 | 2022 | |
| Daiichi Sankyo INC. | $25.63 | 2023 | Injectafer |
| Portola Pharmaceuticals, LLC | $23.35 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $22.47 | 2024 | |
| Atricure, INC. | $21.48 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Scpharmaceuticals INC. | $20.75 | 2024 | |
| Kestra Medical Technology Services, INC. | $16.68 | 2024 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $16.33 | 2023 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $15.52 | 2019 | |
| Amarin Pharma, INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Nishan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.